Eleven states have waiting lists for AIDS drugs

	Tweet

More than 600 low-income AIDS patients in 11 U.S. states are on waiting lists for medicines as funding for assistance programs falls short, a report released on Wednesday said.

Ten other states have had to limit drug coverage or take other steps to control costs for their AIDS Drug Assistance Programs, or ADAPs.

Paid for mostly by the federal government, ADAPs often are the last resort for patients with no other funding for their medications. About 136,000 people annually receive ADAP services.

Overall, ADAP budgets rose 11 percent in fiscal 2004 from the previous year, thanks to increased state funding, drug rebates and higher federal appropriations. Thirty-eight states were able to provide more people with medicines, the report said.

But 11 states had to close enrollment, leaving 627 patients as of March 2005 on waiting lists for prescription drugs to suppress the HIV virus that causes AIDS.

“The growing number of people who need HIV medications, and rising drug costs, continue to exceed available resources,” said Jennifer Kates, director of HIV policy at the Kaiser Family Foundation, a nonprofit health research organization.

The foundation compiled the report with the National Association of State and Territorial AIDS Directors.

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]